Merck KGaA said it was in talks with private equity firms and other investors to share the cost of some clinical trials, part of the German healthcare group’s effort to secure long-term growth. Merck, which is seeking to rebuild a drugs pipeline weakened by a slew of setbacks, is vying with much larger global rivals such as Novartis and Pfizer for licensing deals with biotech research firms. Pharmaceutical companies often team up with each other to share the financial burden of testing drugs, developed either by themselves or biotech firms, on humans.
Help employers find you! Check out all the jobs and post your resume.
